Literature DB >> 23247379

The microenvironment and resistance to personalized cancer therapy.

Shigeo Masuda, Juan Carlos Izpisua Belmonte.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23247379     DOI： 10.1038/nrclinonc.2012.127-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  5 in total

Review 1.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

2.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Authors:  Timothy R Wilson; Jane Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeff Sosman; Antoni Ribas; Jiang Li; John Moffat; Daniel P Sutherlin; Hartmut Koeppen; Mark Merchant; Richard Neve; Jeff Settleman
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

3.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

Authors:  Yu Sun; Judith Campisi; Celestia Higano; Tomasz M Beer; Peggy Porter; Ilsa Coleman; Lawrence True; Peter S Nelson
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

Review 4.  Overcoming implementation challenges of personalized cancer therapy.

Authors:  Funda Meric-Bernstam; Gordon B Mills
Journal:  Nat Rev Clin Oncol       Date:  2012-07-31       Impact factor: 66.675

5.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors:  Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962
  5 in total
  5 in total

1.  Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.

Authors:  Wei Zhang; Gang Zhao; Kai Wei; Qingxiang Zhang; Weiwei Ma; Qiang Wu; Ti Zhang; Dalu Kong; Qiang Li; Tianqiang Song
Journal:  Med Oncol       Date:  2015-03-07       Impact factor: 3.064

Review 2.  Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review.

Authors:  Asfar S Azmi; Bin Bao; Fazlul H Sarkar
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

3.  CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.

Authors:  Jian Li; Jin-Na Chen; Ting-Ting Zeng; Fan He; Shu-Peng Chen; Stephanie Ma; Jiong Bi; Xiao-Feng Zhu; Xin-Yuan Guan
Journal:  BMC Cancer       Date:  2016-01-13       Impact factor: 4.430

4.  Progression-related loss of stromal Caveolin 1 levels fosters the growth of human PC3 xenografts and mediates radiation resistance.

Authors:  Andrej Panic; Julia Ketteler; Henning Reis; Ali Sak; Carsten Herskind; Patrick Maier; Herbert Rübben; Verena Jendrossek; Diana Klein
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

5.  A 3D fibrous scaffold inducing tumoroids: a platform for anticancer drug development.

Authors:  Yvonne K Girard; Chunyan Wang; Sowndharya Ravi; Mark C Howell; Jaya Mallela; Mahmoud Alibrahim; Ryan Green; Gary Hellermann; Shyam S Mohapatra; Subhra Mohapatra
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.